legal issues - Page 1 | CARLAT PUBLISHING

Clinical Update

Drug Testing and the Legal System

July 1, 2024

Paul A. Bryant, MD, Assistant Professor of Psychiatry; Stephanie Eng, MD, Fellow in Forensic Psychiatry; Melissa Lavoie, MD, Fellow in Forensic Psychiatry. Yale University, New Haven, CT.

Drs. Bryant, Eng, and Lavoie have no financial relationships with companies related to this material.

Urine drug screens are frequently ordered for patients receiving addiction treatment. However, the results of these everyday tests can have outsized consequences for patients involved in the legal system. Here, we provide an overview of how drug testing is used in the legal system and how you can be an advocate for your patient.

Clinical Update

A Clinician’s Guide to Drug Courts

July 1, 2024

Stephen Wemakor, MD and Noah Capurso, MD

Stephen Wemakor, MD, Department of Psychiatry, Yale University, New Haven, CT; Noah Capurso, MD, MHS, Assistant Professor of Psychiatry, Yale University, & Editor-in-Chief, The Carlat Addiction Treatment Report.

Drs. Wemakor and Capurso have no financial relationships with companies related to this material.

Many of your patients with substance use disorders will become involved with the legal system over the course of their work with you, and one of the most common avenues is through the drug
court system. Here, we provide the basics of how drug courts function and review how best to work with these courts when they request information.

EXPERT Q&A

Medicinal Cannabis

September 1, 2022

Deepak Cyril D’Souza, MD

Deepak Cyril D’Souza, MD. Professor of Psychiatry, Yale University School of Medicine. Psychiatrist, VA Connecticut Healthcare System, New Haven, CT. Dr. D’Souza, expert for this educational activity, has disclosed that he owns stocks in Jazz Pharmaceuticals and Biohaven Pharmaceuticals. Dr. Capurso has reviewed the content of this interview and determined that there is no commercial bias as a result of these financial relationships.

Laws permitting the use of cannabis for medicinal purposes are being passed around the country, but what are we to make of this new and evolving legal patchwork? Dr. D’Souza describes the process and implications of state-specific legislation, and reviews the evidence, or lack thereof, for cannabis treatment of psychiatric disorders.

CLINICAL UPDATE

Currently Available Cannabis Products

September 1, 2022

Alex K. Rahimi, MD

Alex K. Rahimi, MD. Addiction Psychiatrist, Fort Belvoir Community Hospital, VA. Assistant Professor of Psychiatry, Uniformed Services University, Bethesda, MD. Dr. Rahimi, author for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

The sale of medical and recreational cannabis products has become big business as the prevalence of cannabis use increases across the country. There has been an explosion in the number of available products and their potency. Here, we go over what sorts of products are on the market now and what the implications for our patients.